|
KR20170117185A
|
|
Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
|
|
US2015359794A1
|
|
Impairment of the large ribosomal subunit protein rpl24 by depletion or acetylation
|
|
US2017274048A1
|
|
Methods and compositions for modulating the imune system
|
|
CN106163557A
|
|
For killing senile cell and for treating the method and composition of diseases associated with senescence and disease
|
|
TW201536324A
|
|
Methods for enhancing effectiveness of medical therapies
|
|
WO2014151364A1
|
|
Improved cognitive supplements
|
|
US2014128352A1
|
|
Compounds and methods for modulating mitochondrial metabolism and reactive oxygen species production
|
|
EP2882304A1
|
|
Multi-component formulation for improving neurological function
|
|
CN104270945A
|
|
APP specific BACE inhibitors (ASBIS) and uses thereof
|
|
US2013288981A1
|
|
Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
|
|
US2013288980A1
|
|
Targeting senescent and cancer cells for selective killing by interference with foxo4
|
|
EP2814491A1
|
|
Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions
|
|
US2014335074A1
|
|
Methods for improving medical therapies
|
|
US2015017148A1
|
|
Netrin loop peptide mimetics and uses thereof
|
|
WO2013026021A2
|
|
Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease
|
|
US2013017274A1
|
|
Low dose lithium in the treatment or prophylaxis of parkinson's disease
|
|
AU2003251920A8
|
|
Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression
|
